EF001 其他信息 其他信息 不適用 發行人董事 本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤先生、謝炘先生及田舟山先生，以及五位獨立非 第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國生物製藥有限公司 | | 股份代號 | 01177 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 二零二五年度末期股息 | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.05 ...

（於開曼群島註冊成立之有限公司） 網站：www.sbpgroup.com （股票編號：1177） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本集團旗下企業分佈於北京、上海、南京、連雲港等地，擁有多個藥品生產基地。本集團成立至 今，持續取得卓越成就和穩健發展，核心成員企業包括正大天晴藥業集團股份有限公司（「正大天 晴」）、北京泰德製藥股份有限公司（「北京泰德」）、禮新醫藥科技（上海）有限公司（「禮新醫藥」）、杭 州赫吉亞生物醫藥有限公司（「赫吉亞」）、南京正大天晴製藥有限公司（「南京天晴」）、江蘇正大清 江製藥有限公司（「正大清江」）、江蘇正大豐海製藥有限公司（「正大豐海」）、invoX Pharma Limited （「invoX」）。 截至二零二五年十二月三十一日止年度業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至十二月三十一日止年度 | | | | | 二零二五年 | 二零二四年 | ...

Core Viewpoint - China National Pharmaceutical Group (1177.HK) has achieved a significant upgrade in its ESG rating from A to AA by MSCI, surpassing the industry average in the process [1][2]. Group 1: ESG Rating and Recognition - MSCI is a leading global ESG rating agency, covering over 17,000 listed entities, and is a key reference for institutional investors [2]. - China National Pharmaceutical Group has voluntarily disclosed ESG reports for ten consecutive years since 2017, demonstrating its commitment to sustainable development [2]. - The company has been recognized as the only pharmaceutical company on the Forbes China "2024-2025 Sustainable Development Industrial Enterprises" main list [6]. Group 2: Environmental Initiatives - The company has actively responded to China's "dual carbon" goals, being the first in the pharmaceutical industry to publish a carbon neutrality target plan [3]. - Major pollutant emissions intensity has decreased by over 10% annually for five consecutive years, with a goal to achieve simultaneous reduction in total carbon emissions and intensity by 2025 [3]. Group 3: Social Responsibility and Contributions - Over the past three years, the company has invested more than 13 billion yuan in R&D, with an annual growth rate exceeding 15% [5]. - The company has collaborated with over 30 biotech and biopharma firms, contributing to global health initiatives [5]. - It has donated over 150 million yuan in the past three years to support disaster relief, rural revitalization, and accessible healthcare [5]. Group 4: Awards and Achievements - The company ranks in the top 6% of global pharmaceutical companies according to S&P Global's CSA score and is in the top 3% of all industries in China [6]. - It has received multiple awards for its ESG initiatives, including the "ESG Public Welfare Pioneer" and recognition in the Harvard Business Review case library [6].

Core Viewpoint - China Biopharmaceutical (01177) has achieved an upgrade in its MSCI ESG rating from A to AA, reflecting its leadership in ESG practices among global pharmaceutical companies [2]. Group 1: Stock Performance - As of March 24, 2026, China Biopharmaceutical's stock closed at 5.84 yuan, up 2.1% from the previous trading day [1]. - The stock opened at 5.78 yuan, reached a high of 5.87 yuan, and a low of 5.78 yuan, with a trading volume of 1.56 billion yuan [1]. - The stock has a 52-week high of 9.12 yuan and a low of 3.14 yuan [1]. Group 2: ESG Rating and Practices - The upgrade to AA in the MSCI ESG rating indicates high recognition of the company's management systems and practices in environmental, social, and governance areas [2]. - The company implements a "CARE" core strategy focusing on disease treatment, pharmaceutical accessibility, win-win relationships, and environmental friendliness [2]. - In terms of environmental efforts, the company has reduced major pollutant emission intensity by over 10% annually for five consecutive years and aims for a dual decrease in total carbon emissions and intensity by 2025 [2]. - Three subsidiaries have been awarded national "Green Factory" status [2]. Group 3: Social Responsibility and Innovation - Over the past three years, the company has invested more than 13 billion yuan in R&D, serving over 160 million patients with its key products [2]. - The company has strengthened its innovation pipeline through acquisitions of companies like Lixin Pharmaceutical and Hegia, and has established a global partnership with Sanofi for the exclusive licensing of Rovafexin [2]. - The company has donated over 150 million yuan in the last three years, actively participating in disaster relief, rural revitalization, and inclusive healthcare initiatives [2].

Group 1: ESG Development - The company has established a three-year ESG development plan since 2021, aiming to create a scientific planning system that promotes both long-term and short-term goals [2] - The first ESG three-year plan for 2024 has been successfully completed, achieving key objectives such as a sound ESG system, comprehensive risk management, and industry-leading governance levels [2] - The second ESG three-year plan for 2025 is in full implementation, focusing on innovative actions to set a benchmark for sustainable development in the Chinese pharmaceutical industry [2] Group 2: Environmental Initiatives - The company actively responds to China's "30·60" dual carbon goals and has been the first in the pharmaceutical industry to release a carbon neutrality target plan [2] - Major pollutant emission intensity has decreased by over 10% annually for five consecutive years, contributing to the goal of carbon peak [2] - By 2025, the company aims to achieve simultaneous reductions in both total carbon emissions and intensity, supporting national carbon peak objectives [2] Group 3: Social Responsibility - The company adheres to the philosophy of "health technology, warming more lives," addressing unmet clinical needs by providing high-quality and affordable medical resources [3] - Over the past three years, the company has invested more than 13 billion yuan in R&D, with an annual growth rate exceeding 15% [3] - The company collaborates with over 30 biotech, biopharma, and multinational companies, contributing to global health initiatives [3] - Key products have served over 160 million patients in the past three years, with 13 rare disease drugs in clinical stages or above [3]

Core Viewpoint - China Biopharmaceutical (01177.HK) has achieved an upgrade in its MSCI ESG rating from A to AA, establishing itself as a leader in ESG practices among global large pharmaceutical companies [1][4] Group 1: ESG Governance - The company has developed and continuously improved its ESG governance system, with the board as the highest decision-making body and "CARE" as the core ESG strategy, focusing on Cure, Accessible, Relationship, and Environmental [1] - The company integrates sustainable development concepts into corporate decision-making and business operations [1] Group 2: Environmental Initiatives - The company actively responds to the national "30·60" dual carbon goals, embedding green development concepts into its operations [2] - It has been a pioneer in the pharmaceutical industry by announcing carbon neutrality goals and has achieved over 10% annual reduction in major pollutant emissions for the past five years [2] - The company aims to synchronize the reduction of carbon emission intensity and total emissions by 2025, marking significant progress towards its carbon peak milestone [2] - Three of its subsidiaries have been recognized as national "green factories" [2] Group 3: Social Responsibility - The company adheres to the operational philosophy of "Health Technology, Warming More Lives," focusing on international innovation strategies to upgrade its business and fill clinical gaps [3] - It has invested over RMB 13 billion in R&D over the past three years and has established an international R&D platform [3] - The company has made strategic acquisitions to expand its innovation pipeline and technical platforms, including the full acquisition of Lixin Pharmaceutical Technology and Hejiya Biopharmaceutical [3] - It has served over 160 million patients with its key products in the past three years [3] - The company emphasizes talent development through employee care programs and training initiatives [3] - It has donated over RMB 150 million in the past three years to support disaster relief, rural revitalization, and inclusive healthcare [3] Group 4: Future Outlook - The upgrade to AA rating signifies high recognition of the company's ESG management and practices, marking a milestone in its commitment to sustainable development and corporate social responsibility [4] - The company aims to continue deepening its practices across environmental, social, and governance dimensions while leading the industry towards collaborative development [4] - It seeks to promote green and high-quality development in China's pharmaceutical health industry, creating sustainable shared value for stakeholders [4]

Core Viewpoint - The company has achieved an upgrade in its MSCI ESG rating from A to AA, establishing itself as a leader in ESG practices among global pharmaceutical companies [1][4]. Group 1: ESG Governance - The company has developed a comprehensive ESG governance system, with the board as the highest decision-making body, and has implemented the "CARE" strategy focusing on Cure, Accessible, Relationship, and Environmental aspects [1]. - The company integrates sustainable development principles into its decision-making and business operations [1]. Group 2: Environmental Responsibility - The company actively responds to China's "30·60" dual carbon goals, embedding green development concepts into its operations [2]. - It has been recognized as a green responsibility enterprise, being the first in the pharmaceutical industry to announce carbon neutrality goals, achieving over 10% annual reduction in major pollutant emissions for five consecutive years [2]. - The company aims to achieve simultaneous reductions in carbon emission intensity and total emissions by 2025, marking significant progress towards its carbon peak milestone [2]. - Three subsidiaries have been awarded national "green factory" titles, reflecting the company's commitment to green development [2]. Group 3: Social Responsibility - The company adheres to the operational philosophy of "health technology, warming more lives," focusing on international innovation strategies to enhance business and fill clinical gaps [3]. - Over the past three years, the company has invested more than RMB 13 billion in R&D, establishing an international R&D platform and acquiring innovative pharmaceutical companies to expand its pipeline [3]. - The company has served over 160 million patients with its key products in the last three years [3]. - It emphasizes talent development through initiatives like the Employee Assistance Program (EAP) and has donated over RMB 150 million to charitable causes in the past three years [3]. Group 4: Future Outlook - The upgrade to AA rating signifies high recognition of the company's ESG management and practices, marking a milestone in its commitment to sustainable development and corporate social responsibility [4]. - The company aims to continue deepening its practices across environmental, social, and governance dimensions while leading the industry towards collaborative development [4]. - It seeks to promote high-quality, sustainable development in China's pharmaceutical health industry, creating shared value for stakeholders and establishing itself as a global ESG benchmark [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份編號：1177） 自願公告 MSCI ESG評級升至AA級 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集 團憑借在環境、社會及管治(ESG)領域的系統佈局、持續深耕與卓越實踐，Morgan Stanley Capital International (MSCI) ESG評級由A級升至AA級，成為全球大型藥企ESG實踐的卓越領導者。 1 在社會責任領域，本集團切實踐行「健康科技，溫暖更多生命」的運營理念，以國際化創新戰略為引 領，積極推動業務升級，填補臨床空白，為更多患者的健康權益提供堅實保障。近年來，本集團研 發投入持續提升，近三年研發費用累計超過人民幣130億元。同時，本集團搭建國際化研發平台，開 展一系列精準化投資併購，全資收購禮新醫藥科技（上海）有限公司（「禮新醫藥」）、杭州赫吉亞生物 醫藥有限公司（「赫吉亞 ...

Group 1 - The Hong Kong pharmaceutical industry outperformed the Hang Seng Index in February, with the Hang Seng Healthcare Index declining by 2.2%, which is less than the overall Hang Seng Index decline [1] - The central government has officially classified biomedicine as an emerging pillar industry, indicating strong future support for the biopharmaceutical sector [2] - The total amount of innovative drugs exported in January exceeded 33.2 billion RMB, approaching a quarter of the total for the entire year of 2025, reflecting increasing recognition of Chinese innovative drugs by overseas pharmaceutical companies [1] Group 2 - China National Pharmaceutical Group announced the acquisition of Haogiya Biotech, a pioneer in small nucleic acid fields, and granted Sanofi exclusive rights for the global development and commercialization of Rovafatinib, with potential payments up to 1.53 billion USD [3] - The company is expected to achieve double-digit growth in product sales revenue by 2025, bolstered by the acquisition and the successful licensing of Rovafatinib, which indicates strong recognition of its R&D capabilities by global industry leaders [3] - The CXO sector leaders, WuXi Biologics and WuXi AppTec, are also recommended due to their positive earnings forecasts for 2025 and strong demand for new projects, supported by the government's increasing backing for innovative drugs [3]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Beijing Tide Pharmaceutical Co., has received clinical trial approval from the NMPA for its first-in-class innovative drug TRD221, aimed at treating osteoarthritis [1][2] Group 1: Company Developments - TRD221 is a complex polysaccharide drug developed in collaboration with the Chinese Academy of Medical Sciences, showcasing good biocompatibility and safety [1] - The drug acts as a key protein regulator that inhibits the release of inflammatory factors from the complement system, thereby promoting cartilage repair and delaying disease progression [1] Group 2: Industry Context - Osteoarthritis (OA) is a degenerative disease affecting joint cartilage, with approximately 595 million patients globally in 2020, expected to rise to 642 million by 2050 [2] - The prevalence of primary OA among individuals over 40 in China has reached 46.3%, with an increasing trend due to an aging population [2] - Current OA treatments primarily focus on pain relief, with significant unmet clinical needs in delaying disease progression and improving joint function [2] - TRD221 has shown dual effects in animal models by alleviating pain symptoms and improving structural damage, indicating its potential as a new treatment option for OA [2]